AKAM vs KALV · P/E 27, rev $2.17B vs rev $13.7M
Akamai Technologies Inc (AKAM) versus Kalvista Pharmaceuticals Inc (KALV) — a side-by-side from cached financials, not a winner call.
Akamai Technologies Inc (AKAM) is a software - infrastructure company listed on US.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Latest reported AKAM revenue for 2026-06-30 was $2.17B. Net income was $185.7M. AKAM currently screens at market cap $11.31B and trailing P/E 26.7.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
AKAM currently screens at market cap $11.31B and trailing P/E 26.7. KALV currently screens at market cap $1.44B.
Not investment advice. Open the AKAM and KALV stock pages for the full models.
Not investment advice.